BEIJING - The Chinese government on Friday released a circular on ensuring drug safety for children, raising requirements on various aspects such as research and development, supply and quality management.

Released by six departments, including the National Health and Family Planning Commission and China Food and Drug Administration, the document noted that pharmaceutical companies lack motivation to research and develop medicines fit for children, and the improper use of medicines still exists.

According to the document, medicines in urgent need for clinical use should enjoy green channels when applying for official approvals, and a list of drugs that should enjoy priority in research and development will be compiled to guide drug companies.

Meanwhile, companies must provide results of clinical trials and other related data for products on the market as well as those awaiting approvals as references for future research and supervision.

The circular said favorable policies will support companies to upgrade children's products and price them moderately, and the government will coordinate manufacturing, procurement and storage of medicines that are crucial and might easily run out for clinical use.

According to the circular, health authorities will draft an official manual for children's use of medicines, and companies must revise and improve their product manuals.